Indian Patent Office Proposes Overhaul of Pharma and Biotech Patent Examination Guidelines

The Indian Patent Office (搜索)搜索该词条 (IPO) has proposed updating its guidelines for the examination of pharmaceutical patent applications, issuing draft guidance dated September 4, 2026, that aims to improve the quality, consistency and uniformity of scrutiny by incorporating the evolving interpretation of laws by courts. The office simultaneously issued draft guidelines for the examination of applications in the field of biotechnology, replacing older frameworks that have been in place since 2013 and 2014.

The IPO, which operates under the Ministry of Commerce and Industry (搜索)搜索该词条, said the guidelines are intended to help examiners and controllers achieve consistently uniform standards of patent examination. "In an attempt to bring in quality, consistency and uniformity, the office has introduced the guidelines for examination in certain key areas like pharmaceuticals," the office stated.

Aligning Examination Practice With Judicial Standards

According to the draft guidelines, many issues related to product patenting in pharmaceuticals are now becoming clear through court decisions. "Therefore, there is a need to update guidelines for examination of pharmaceutical patents, incorporating the analysis of the courts, with the objective that the guidelines shall help in improvement of the examination standard and shall introduce harmonious practice amongst the technical officers of the system," the draft states.

The IPO framed the stakes in broad terms, noting that pharmaceutical patenting in India is "extremely important and a sensitive issue because a bad patent can become a burden to society; good patents are essential for promoting innovation and technological development in the country." It added that Indian pharmaceutical patenting is of utmost concern not only to the people of India but also to the world community, as India has emerged as the pharmacy of the world.

The draft guidelines specifically address complex technical areas, including biotechnological innovations and the controversial Section 3(d) of the Patents Act. Section 3(d) is often referred to as an "anti-evergreening" clause, designed to prevent companies from extending the life of a patent by making only minor, non-innovative changes to an existing drug. By integrating recent court rulings into the examination manual, the Patent Office is setting clearer boundaries on what qualifies as a genuine invention.

Biotechnology Applications Face Distinct Challenges

For biotechnology applications, the draft identifies issues of serious concern to users of the patent system, including novelty, obviousness, industrial applicability, sufficiency of disclosure and clarity in claims. It also flags special issues that have evolved, such as moral and ethical concerns, environmental safety, patenting of ESTs (Expressed Sequence Tags) of partial gene sequences, cloning of farm animals, stem cells, and gene diagnostics.

"Thus, the patenting of inventions in the field of biotechnology poses challenges to the applicants for patents as well as to the Patent Office," the draft states, adding that there is an "urgent need" to establish uniform and consistent practices for examining applications in biotechnology and allied subjects under the Patents Act, 1970 (as amended).

Industry Weighs Predictability Against New Burdens

Mohit Singh, Partner at One Law Partners (搜索)搜索该词条, said the draft guidelines should resolve a long-standing gap between patent office practice and the law that has emerged over time through judicial pronouncements. "The incorporation of judicial standards, such as the Delhi High Court's 'Seven Stambhas' framework for assessing novelty, will make the examination process more consistent and predictable," he said. The guidelines also reflect the need for India's patent examination system to keep pace with developments in the global biopharma sector, he added.

"The key benefit of these new guidelines for industry would be greater predictability and certainty around R&D investments and the value of IP, particularly in the biopharma sector," Singh said.

The shift toward stricter and more standardized scrutiny presents a double-edged sword for pharmaceutical and biotech firms. On one hand, it offers better predictability, as companies will know exactly what criteria they must meet to obtain a patent. On the other, the heightened focus on disclosure and novelty means applications with insufficient data or only minor changes are more likely to face rejection, potentially increasing the complexity and cost of the patent-filing process for R&D-heavy companies.

Comment Window Draws Concern

The industry is currently reviewing the proposals, with a public comment window set to close on September 19, 2026. The tight two-week timeline has raised concerns among industry experts, who argue that the brief window may not allow sufficient time to address all the technical challenges embedded in the draft. If the guidelines are implemented without adequately addressing these concerns, firms may face a more difficult regulatory environment.

For investors, the key monitorable will be how the stricter guidelines affect the long-term success rate of new drug applications. As companies strive to maintain their competitive advantage through innovation, the ability to secure robust patent protection remains essential for future revenue. Investors may track management commentary in upcoming earnings calls to see how major pharmaceutical and biotech firms are preparing their intellectual property strategies to align with these evolving regulatory standards.